When patients were stratified by average plasma sunitinib concentration (< median vs. ≥ median, respectively), incidences were neutropenia [17.2% (5/29 patients) vs. 60.0% (n = 18/30)], increased ALT [6.9% (2/29) vs. 43.3% (n = 13/30)], increased AST [3.4% (1/29) vs. 40.0% (n = 12/30)], hypertension [0% vs. 33.3% (n = 10/30)], lymphopenia [13.8% (4/29) vs. 40.0% (n = 12/30)], thrombocytopenia [3.4% (1/29) vs. 40.0% (n = 12/30)], and leukopenia [24.1% (7/29) vs. 56.7% (n = 17/30)]. This evidence concerns the gene GPT and neutropenia.